[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-359484-105":59,"doc-detail-359484-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","targeted-drug-delivery-systems-for-pancreatic-cancer-therapy-advances-challenges-and-future-perspectives","Targeted drug delivery systems for pancreatic cancer therapy - advances, challenges, and future perspectives","","The review summarizes recent advances, challenges, and future perspectives in targeted drug delivery systems (DDSs) for pancreatic cancer therapy. Pancreatic cancer outcomes are constrained by dense desmoplastic stroma, profound hypoxia, limited T-cell infiltration, and abundant immunosuppressive myeloid populations that together create physical and immunological barriers. Organic, inorganic, and biological DDS platforms are discussed for enhancing tumor accumulation, reducing off-target toxicity, and adapting delivery to the tumor microenvironment with internal cues or external stimuli. Strategies to remodel the immunosuppressive tumor microenvironment, enable stroma–immune co-modulation, and support biomarker-guided precision approaches are also addressed.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/targeted-drug-delivery-systems-for-pancreatic-cancer-therapy-advances-challenges-and-future-perspectives/359484/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/targeted-drug-delivery-systems-for-pancreatic-cancer-therapy-advances-challenges-and-future-perspectives/359484.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"Why is targeted drug delivery especially important for pancreatic cancer therapy?","Question",{"text":112,"@type":113},"Pancreatic cancer has a dense desmoplastic stroma, profound hypoxia, limited T-cell infiltration, and abundant immunosuppressive myeloid populations. These create both physical and immunological barriers that hinder effective treatment delivery and responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What types of targeted DDS platforms are reviewed for pancreatic cancer?",{"text":117,"@type":113},"The review covers organic, inorganic, and biological platforms, including liposomes/lipid nanoparticles, polymeric nanoparticles, carrier-free self-assembly systems, hybrid inorganic–organic nanomaterials, and biomimetic carriers such as exosomes and protein nanocages.",{"name":119,"@type":110,"acceptedAnswer":120},"How do DDS approaches help address immunosuppression in the tumor microenvironment?",{"text":121,"@type":113},"DDSs are designed to remodel the immunosuppressive tumor microenvironment by reprogramming tumor-associated macrophages, inhibiting myeloid-derived suppressor cells, activating innate immune sensing pathways, and overcoming stromal immune exclusion via stroma–immune co-modulation or penetration mechanisms.",{"name":123,"@type":110,"acceptedAnswer":124},"What does the review propose for future development and clinical translation?",{"text":125,"@type":113},"Future work should prioritize clinically actionable combination strategies and appropriate localized/depot delivery. It also emphasizes biomarker-guided patient stratification and data-driven design/optimization, including artificial intelligence and machine learning, to accelerate personalized, translatable DDSs.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},359484,1790194593,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Review  \nPUBLISHED 26 March 2026  \nDOI 10.3389/fimmu.2026.1785625  \nOPEN ACCESS  \nEDITED BY  \nMd Sadique Hussain,  \nUttaranchal University, India  \nREVIEWED BY  \nJindong Xie,  \nSun Yat-sen University Cancer Center (SYSUCC), China  \nMyrto Ischyropoulou,  \nMinerva Imaging, Denmark  \n*CORRESPONDENCE  \nDeshi Dong  \n [dongdeshi@dmu.edu.cn](dongdeshi@dmu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 12 January 2026  \nREVISED 27 February 2026  \nACCEPTED 27 February 2026  \nPUBLISHED 26 March 2026  \nCITATION  \nZhang X, Tao X, Zhang Y, Gan G, Lv J, Zhang L and Dong D (2026) Targeted drug delivery systems for pancreatic cancer therapy: advances, challenges, and future perspectives.  \nFront. Immunol. 17:1785625 .  \ndoi: 10.3389/fimmu.2026.1785625  \nCOPYRIGHT  \n© 2026 Zhang, Tao, Zhang, Gan, Lv, Zhang and Dong. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTargeted drug delivery systems for pancreatic cancer therapy:  \nadvances, challenges, and future perspectives  \nXiaonan Zhang 1,2†, Xufeng Tao 1†, Yunshu Zhang 1,2,  \nGuangshuo Gan 1, Jing Lv 1, Lu Zhang 1 and Deshi Dong 1,2* 1 Department of Pharmacy, First Afﬁliated Hospital of Dalian Medical University, Dalian, Liaoning, China, 2 Institute (College) of Integrative Medicine, Dalian Medical University, Dalian, Liaoning, China  \nThe review summarizes recent advances, challenges, and future perspectives in targeted drug delivery systems (DDSs) for pancreatic cancer (PC) therapy. Given the dismal prognosis of PC treatment is hindered by a dense desmoplastic stroma, profound hypoxia, limited T-cell inﬁltration, and abundant immunosuppressive myeloid populations, together forming physical and immunological barriers to effective therapy. Targeted DDSs based on organic, inorganic, and biological platforms (e.g., liposomes/lipid nanoparticles, polymeric nanoparticles, carrier-free drug self-assembly systems, hybrid inorganic–organic nanomaterials, and biomimetic carriers such as exosomes and protein nanocages) can enhance tumor accumulation and reduce off-target toxicity through active ligand–receptor targeting, microenvironment-adaptive delivery, and controlled release triggered by internal cues (pH, enzymes, reactive oxygen species, hypoxia) or external stimuli (light, heat, magnetic ﬁelds) . Importantly, DDSs are designed to remodel the immunosuppressive tumor microenvironment (TME) by reprogramming tumorassociated macrophages, inhibiting myeloid-derived suppressor cells, activating innate immune sensing pathways, and overcoming stromal immune exclusion via stroma–immune co-modulation or transcytosis-enabled penetration. We further discuss precision-medicine opportunities, proposing biomarker-guided stratiﬁcation and monitoring frameworks that link patient-speciﬁc TME features (e.g., stroma-high/immune-excluded, myeloid-dominant, weak innate priming) to rational DDS selection and combination regimens. Future development should prioritize clinically actionable combination strategies, localized/depot delivery when appropriate, and data-driven design and optimization (including artiﬁcial intelligence and machine learning) to accelerate personalized, translatable DDSs for improving pancreatic cancer outcomes.  \nKEYWORDS  \nclinical translation, immune microenvironment, nanocarriers, pancreatic cancer, targeted drug delivery systems  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \n1 Introduction  \nPancreatic cancer (PC) remains a highly fatal malignancy with one of the worst prognoses amongst all cancer types (1–4) . PC rarely shows early clinical m","cbCaiq8P1aaQFGrB","https://ap.wps.com/l/cbCaiq8P1aaQFGrB","pdf",3018556,21,"English","# 1 Introduction\n# 2 Targeted drug delivery strategies for pancreatic cancer\n# 3 Remodeling the immunosuppressive tumor microenvironment\n# 4 Biomarker-guided precision medicine and clinical translation\n# 5 Future perspectives and data-driven design","[{\"question\":\"Why is targeted drug delivery especially important for pancreatic cancer therapy?\",\"answer\":\"Pancreatic cancer has a dense desmoplastic stroma, profound hypoxia, limited T-cell infiltration, and abundant immunosuppressive myeloid populations. These create both physical and immunological barriers that hinder effective treatment delivery and responses.\"},{\"question\":\"What types of targeted DDS platforms are reviewed for pancreatic cancer?\",\"answer\":\"The review covers organic, inorganic, and biological platforms, including liposomes/lipid nanoparticles, polymeric nanoparticles, carrier-free self-assembly systems, hybrid inorganic–organic nanomaterials, and biomimetic carriers such as exosomes and protein nanocages.\"},{\"question\":\"How do DDS approaches help address immunosuppression in the tumor microenvironment?\",\"answer\":\"DDSs are designed to remodel the immunosuppressive tumor microenvironment by reprogramming tumor-associated macrophages, inhibiting myeloid-derived suppressor cells, activating innate immune sensing pathways, and overcoming stromal immune exclusion via stroma–immune co-modulation or penetration mechanisms.\"},{\"question\":\"What does the review propose for future development and clinical translation?\",\"answer\":\"Future work should prioritize clinically actionable combination strategies and appropriate localized/depot delivery. It also emphasizes biomarker-guided patient stratification and data-driven design/optimization, including artificial intelligence and machine learning, to accelerate personalized, translatable DDSs.\"}]","Targeted drug delivery systems for pancreatic cancer therapy - advances, challenges, and future perspectives | PDF",1790137002,53,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/534da825d5697db8f438e87279c9a996.webp",983,1389,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4ac6ed64a2f973bf3bb7527a15d0fe88.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/37d78b37957c9dafc054498ca65a40a5.webp",981,1386,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/643e4c33047b21589647126b15cf231b.webp",980,1385]